{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"5.5","value":"1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Progression Free Survival is defined as the time interval from the start of treatment to documented evidence of disease progression. Progressive disease is at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study longest diameter (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progression).","dispersionType":"95% Confidence Interval","groups":[{"description":"20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)","id":"OG000","title":"IMC-A12 Monotherapy in Patients"}],"paramType":"MEDIAN","populationDescription":"One participant withdrew from the study and was excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"To study completion, an average of 3 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}